Literature DB >> 16440247

[Sealing of percutaneous nephrolithotomy access after complete stone removal with a hemostyptic gelatin powder (Spongostan)].

V Schick1.   

Abstract

PURPOSES: Parallel to the pilot project of Lee et al. which was published in February 2004, we also considered the possibility to seal the percutaneous nephrolithotomy (PCNL) access after complete stone removal via the local amplatz sheath. We started our project with the aims of increasing postoperative patient comfort, minimizing the risk of bleeding, and reducing postoperative cost and length of the hospital stay by performing this minimally invasive technique in 7 patients with medium stone burden.
MATERIALS AND METHODS: All patients were treated by removing stones via a working channel passing through the lower pole calix. After complete stone removal a hemostyptic gelatin powder (Spongostan, Johnson & Johnson) was prepared to a doughy paste, some drops of contrast medium were added and the whole material was introduced through the amplatz sheath into the working channel under imaging control. Imaging-controlled insertion of the doughy gelatin clot through the amplatz sheath into the parenchymal part of the channel alone resulted in immediate hemostasis in all patients. The amplatz sheath was retracted over a 28 Fr. rectal tube which was used to push the gelatin forward. There was no need for an additional tamponade of the renal fat capsule or the abdominal wall. After 2 minutes when no channel bleeding was apparent, the skin sutures were placed.
RESULTS: Bleeding of the nephrostomy tract did not occur in any of the 7 patients. Average operating time was 50 minutes which was not significantly reduced by performing the new procedure. However, the hospital stay was reduced by 2 days. Two of the patients showed a single fever episode during the second postoperative evening. All patients presented with steady postoperative laboratory values without evidence of bleeding. Free urinary flow from the collecting system was controlled by means of ultrasound and urography.
CONCLUSIONS: Similar to the recent usage of FloSeal/Baxter reported by Lee et al. we can confirm very reliable and immediate hemostasis using a pasty preparation of Spongostan (Johnson and Johnson) gelatin powder which was classified as being less toxic by the FDA in 2003 due to the lack of glutaraldehyde and bovine thrombin. Therefore, tubeless PCNL can be used for complete percutaneous clearance of stones without bleeding.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16440247     DOI: 10.1055/s-2005-870960

Source DB:  PubMed          Journal:  Aktuelle Urol        ISSN: 0001-7868            Impact factor:   0.658


  6 in total

Review 1.  Hemostatic plug: novel technique for closure of percutaneous nephrostomy tract.

Authors:  Joel E Abbott; Arman Cicic; Roger W Jump; Julio G Davalos
Journal:  J Endourol       Date:  2014-10-16       Impact factor: 2.942

2.  Totally tubeless percutaneous nephrolithotomy: a prospective randomized controlled study.

Authors:  Chien-Hsing Chang; Chung-Jing Wang; Shi-Wei Huang
Journal:  Urol Res       Date:  2011-02-18

Review 3.  Hemostatic agents used for nephrostomy tract closure after tubeless PCNL: a systematic review and meta-analysis.

Authors:  Cui Yu; Zhou Xu; Wang Long; Liu Longfei; Zeng Feng; Qi Lin; Zu Xiongbing; Chen Hequn
Journal:  Urolithiasis       Date:  2014-07-27       Impact factor: 3.436

4.  New instrumentation in percutaneous nephrolithotomy.

Authors:  Joseph W Pugh; Benjamin K Canales
Journal:  Indian J Urol       Date:  2010-07

5.  Comparative Study between Standard and Totally Tubeless Percutaneous Nephrolithotomy.

Authors:  Sung Il Yun; Yoon Hyung Lee; Jae Soo Kim; Sung Ryong Cho; Bum Soo Kim; Joon Beom Kwon
Journal:  Korean J Urol       Date:  2012-11-14

6.  Hemostatic agents for access tract in tubeless percutaneous nephrolithotomy: Is it worth?

Authors:  Francisco Sepulveda; Alfredo Aliaga; Daniela Fleck; Mario Fernandez; Alejandro Mercado; Roberto Vilches; Francisco Moya; Rodrigo Ledezma; Diego Reyes; Fernando Marchant
Journal:  Urol Ann       Date:  2016 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.